Latest breaking stories, features and analysis
Pfizer is acquiring Global Blood Therapeutics
- Pfizer Inc will get all of GBT’s outstanding shares in a cash agreement of $68.50 per share
- GBT developed a first-in-class drug, Oxbryta tablets that directly attacks the root cause of this disease.
- Oxbyrta's net sales came to about roughly $195 million in 2021.